Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
9.28
-0.03 (-0.32%)
At close: Jul 8, 2026, 4:00 PM EDT
9.18
-0.10 (-1.08%)
After-hours: Jul 8, 2026, 4:04 PM EDT
Xilio Therapeutics Revenue
Xilio Therapeutics had revenue of $12.65M in the quarter ending March 31, 2026, with 331.67% growth. This brings the company's revenue in the last twelve months to $53.48M, up 476.71% year-over-year. In the year 2025, Xilio Therapeutics had annual revenue of $43.77M with 589.88% growth.
Revenue (ttm)
$53.48M
Revenue Growth
+476.71%
P/S Ratio
1.04
Revenue / Employee
$703,737
Employees
76
Market Cap
55.52M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 43.77M | 37.42M | 589.88% |
| Dec 31, 2024 | 6.34M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionXLO News
- 2 days ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Xilio Therapeutics appoints Ben Harshbarger as chief legal officer - TheFly
- 9 days ago - Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer - GlobeNewsWire
- 6 weeks ago - Xilio Therapeutics Registration statement: Registration filing - Filings
- 2 months ago - Xilio Therapeutics files $250M mixed securities shelf - TheFly
- 2 months ago - Xilio Therapeutics Registration statement: Registration filing - Filings
- 2 months ago - Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates - GlobeNewsWire
- 2 months ago - Xilio Therapeutics Earnings release: Q1 2026 - Filings